Key determinants of energy expenditure in cancer and implications for clinical practice von Purcell, S A, Elliott, S A, Baracos, V E, Chu, Q S C, Prado, C M

Volltext

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200 von Chu, Q. S.-C., Nielsen, T.O., Alcindor, T., Gupta, A., Endo, M., Goytain, A., Xu, H., Verma, S., Tozer, R., Knowling, M., Bramwell, V.B., Powers, J., Seymour, L.K., Eisenhauer, E.A.

Volltext

A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell... von Chiappori, A A, Schreeder, M T, Moezi, M M, Stephenson, J J, Blakely, J, Salgia, R, Chu, Q S, Ross, H J, Subramaniam, D S, Schnyder, J, Berger, M S

Volltext

MSM and HIV/AIDS in China von ZHANG, Bei Chuan, CHU, Quan Sheng

Volltext

Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer von Mita, A C, Papadopoulos, K, de Jonge, M J A, Schwartz, G, Verweij, J, Mita, M M, Ricart, A, Chu, Q S-C, Tolcher, A W, Wood, L, McCarthy, S, Hamilton, M, Iwata, K, Wacker, B, Witt, K, Rowinsky, E K

Volltext

EXAFS study of PZT ferroelectric thin films of different crystallinities von Hu, X P, Duan, D W, Zhang, K, Chu, S Q, Zhang, J, Xie, Y N, Guo, D, Cao, J L

Volltext

VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC von Hochmair, M.J., Vermaelen, K., Mountzios, G., Carcereny, E., Dooms, C., Lee, S-H., Morocz, E.M., Kato, T., Ciuleanu, T-E., Dy, G., Parente, M.B.M.C.S., O'Byrne, K.J., Chu, Q.S-C., De Castro, G., Girard, N., Snyder, W., Tran, Q., Kormany, W., Houk, B., Curioni-Fontecedro, A.

Volltext

1460PBiopsy on progression in EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (aNSCLC) patients (pts): A Canadian experience von Chu, Q S-C, Agha, A, Devost, N C, Walton, R, Ghosh, S, Ho, C

Volltext

Biopsy on progression in EGFR mutation positive (EGFRm) advanced non-small cell lung cancer (aNSCLC) patients (pts): A Canadian experience von Chu, Q.S.-C., Agha, A., Devost, N.C., Walton, R., Ghosh, S., Ho, C.

Volltext

Phase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable metastatic... von Johnson, M.L., Patel, M.R., Ulahannan, S.V., Hansen, A., George, B., Chu, Q.S.-C., Elgadi, M., Ge, M., Duffy, C., Graeser, R., Khedkar, S., Jones, S.F., Burris, H.

Volltext

1243TiPPhase I study of BI 754111 (anti-LAG-3) plus BI 754091(anti-PD-1) in patients (pts) with advanced solid cancers, followed by expansion in pts with microsatellite stable meta... von Johnson, M L, Patel, M R, Ulahannan, S V, Hansen, A, George, B, Chu, Q S-C, Elgadi, M, Ge, M, Duffy, C, Graeser, R, Khedkar, S, Jones, S F, Burris, H

Volltext

Targeted therapy for incurable solid cancers: A meta-analysis von Conter, H. J., Sengupta, R., Conter, D., Colman, I., Chu, Q. S.

Volltext

Phase II trial of consolidation chest radiotherapy for extensive-stage small cell lung cancer von Yee, D., Butts, C. A., Chu, Q. S., Fenton, D. W., Joy, A., Reiman, T. J., Smylie, M., Roa, W.

Volltext

Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage... von Chiappori, A., Schreeder, M. T., Moezi, M. M., Stephenson, J., Blakely, L., Salgia, R., Chu, Q. S., Ross, H. J., Subramaniam, D. S., Berger, M. S.

Volltext

An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC) von Gandhi, L., Chu, Q. S., Stephenson, J., Johnson, B. E., Govindan, R., Bonomi, P., Eaton, K., Fritsch, H., Munzert, G., Socinski, M.

Volltext

A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC) von Chiappori, A., Schreeder, M. T., Moezi, M. M., Stephenson, J., Blakely, J. L., Salgia, R., Chu, Q. S., Malik, S. M., Modiano, M. M., Berger, M. S.

Volltext

A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) von Ellis, P. M., Chu, Q. S., Leighl, N. B., Laurie, S. A., Trommeshauser, D., Hanft, G., Munzert, G., Gyorffy, S.

Volltext

An open label safety and efficacy phase 2a study of the N-cadherin (N-cad) antagonist ADH-1 in subjects with N-cadherin expressing solid tumors von Chu, Q. S., Knox, J., Batist, G., Venner, P., Chi, K. N., Woods, L., Burris, H. A., Malik, R. K., Peters, W. P., Jonker, D. J.

Volltext

Development of pressure-modulated EXAFS method von 储胜启 郑黎荣 车容钲 周爱玉 张静 刘景 胡天斗

Volltext

Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: Results of a phase I study von Mita, M. M., Mita, A. C., Goldston, M., Chu, Q. S., Tolcher, A. W., Ricart, A., Desai, P., Okereke, C. S., Rowinsky, E. K., Takimoto, C.

Volltext